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Abstract 
Technology Commercialization Assessment: 
Near Infrared Wound Healing Monitor 
Adam J. Greenspan 
 
 
 
 
The following report is intended to examine the commercial viability of the 
Diabetic wound monitor using near infrared (NIR) spectroscopy, which is currently under 
development at Drexel University.  The market conditions shall favor the introduction of 
this technology, as it not only addresses a currently unmet need, but also is expected to 
appeal to multiple and distinct groups of end users.  The overall wound care management 
market exceeds $20 billion in the U.S., and the global wound care therapies market is 
growing at an 8% rate annually and forecast to reach $7.3 billion by 2013.  With a global 
yearly incidence of ulcers at 37 million reported cases with more than half comprised of 
diabetic ulcers, there is a tremendous demand for an accurate assessment of wound 
healing.  The ability to accurately assess wound healing would allow for a change in the 
course of therapy long before it becomes clinically obvious.  The associated cost saving 
potential is substantial, providing a solid foundation in the pursuit of medical 
reimbursement for the clinical application of this technology.          
From a development standpoint, the technology readiness level (TRL) is 
characterized as having nearly advanced to the midway point.  The concept has been 
proven in animal models and in early human clinical trials to constitute a preliminary 
proof-of-concept.  The first generation device prototype measures absorption and 
scattering coefficients of tissue in the range of 685 - 830 nm, where differences in 
absorption reveal changes in tissue oxygenation and blood flow, while differences in 
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scattering correlate to tissue structure and inflammation.  In all studies, the performance 
was stable as both healing and non-healing wounds consistently yielded values of the 
NIR absorption coefficient μa at the wound center and wound edges greater than values 
of μa at the control (non-wound) sites.  This trend would be expected due to the reduced 
absorption characteristic of deoxygenated hemoglobin present at the wound site. 
A failure mode and hazard analysis indicates that the device is headed toward the 
designation of generally regarded as safe (GRAS).  While there are some minor 
refinements to consider in the engineering design, the element of risk associated with this 
device shall be considered low.  A preliminary review of the regulatory pathway suggests 
that such a device would only require a 510(k) FDA approval, and a combination of 
predicate devices has been identified.  The primary barrier to entry will comprise the 
intellectual property rights attainable for the present technology.  A small portfolio of 
pending patents shall provide some protection, and its value shall be further assessed 
through a comprehensive patent landscape analysis.  A preliminary landscape has 
identified a list of potential competitors and commercial partners provided herein. 
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Chapter 1. Project Overview 
1.1. Background Information 
 Reference Numbers: Drexel docket numbers 08-0908D, 08-0907D, 08-0974D 
 Public Disclosure Dates:  
 Priority Dates: 21-Apr-2008,  
 Protection Status: Patent pending 
o Provisional applications:  
 61/046,640, "CORRELATION OF NEAR INFRARED 
ABSORPTION (fNIR) AND DIFFUSE REFLECTANCE 
SPECTROSCOPY SCATTERING (DRS) WITH TISSUE 
NEOVACULARIZATION AND COLLAGEN 
CONCENTRATION" 
 61/054,535, "METHODS FOR MEASURING CHANGES IN 
OPTICAL PROPERTIES OF TISSUE DURING ACUTE 
WOUND HEALING" 
 61/111,924, "NON-CONTACT FREQUENCY DOMAIN NEAR 
INFRARED ABSORPTION (fNIR) DEVICE FOR ASSESSING 
TISSUE DAMAGE" 
o PCT applications: 
 WO 2009/131,989 “METHODS FOR MEASURING CHANGES 
IN OPTICAL PROPERTIES OF WOUND TISSUE AND 
CORRELATING NEAR INFRARED ABSORPTION (FNIR) 
AND DIFFUSE REFLECTANCE SPECTROSCOPY 
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SCATTERING (DRS) WITH TISSUE 
NEOVASCULARIZATION AND COLLAGEN 
CONCENTRATION TO DETERMINE WHETHER WOUND IS 
HEALING” 
 
1.2. Inventor Information 
  
  
 
Table 1: Listing of Inventors and Basic Information 
 
 
 
 
1.3. Brief Technical Description 
 Near Infrared (NIR) Spectroscopy is a new, non-invasive technique in which to 
analyze structural and functional information of living tissues in the region of 
wavelength 680 - 900 nm.  
Inventor Name Position Primary Affiliation Inventions 
Disclosed 
Elizabeth S. Papazoglou, 
Ph.D. 
Faculty Drexel University, School 
of Biomedical 
Engineering 
2 
Michael S. Weingarten, 
MD, MBA 
Clinician, Faculty Drexel University, 
College of Medicine 
2 
Leonid Zubkov, D.Sc. 
Research Faculty Drexel University, School 
of Biomedical 
Engineering 
2 
Linda Zhu, M.S. 
Research Assistant Drexel University, School 
of Biomedical 
Engineering 
2 
Michael Neidrauer, M.S. 
Research Assistant Drexel University, School 
of Biomedical 
Engineering 
2 
Kambiz Pourrezaei 
Research Faculty Drexel University, School 
of Biomedical 
Engineering 
2 
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 The present device measures absorption and scattering coefficients of tissue in the 
range of 685 - 830 nm with one source and four detectors.   
 Frequency domain NIR spectroscopy allows the user to definitely separate healthy 
and diabetic tissue.  
 Differences in absorption reveal changes in tissue oxygenation and blood volume, 
while differences in scattering correlate to tissue structure and inflammation. 
 
1.4. Wound Healing Overview 
Wound healing is a continuous process, consisting of overlapping phases.  
Coagulation begins immediately after injury, and inflammation is initiated shortly 
thereafter.  The blood coagulates to establish hemostasis, or clotting, through the 
formation of a fibrin plug.  The plug comprises platelets embedded in a polymerized 
fibrin network, which provides a provisional extracellular matrix (ECM) for cell 
migration.  This not only provides temporary wound coverage, but also creates an 
enclosed environment for the platelets to aggregate and release a wide range of growth 
factors, including platelet-derived growth factor (PDGF) and transforming growth factor 
(TGF)1 [1].  These and other growth factors actively recruit inflammatory cells to the 
wound.   Infiltrating neutrophils cleanse the wounded area of foreign particles and 
bacteria and are then extruded by macrophages [1].  Macrophages also secrete cytokines 
and growth factors, which stimulate the infiltration, proliferation, and migration of 
fibroblasts and endothelial cells as part of angiogenesis.  Fibroblasts and endothelial cells 
convert molecular oxygen to superoxide, which contributes to infection resistance and 
oxidative signaling to promote further growth factor secretion.  Overall, the inflammatory 
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process is a defense against infections and a bridge between tissue injury and new cell 
growth. 
As the inflammatory phase subsides, epithelialization begins as an epidermal 
covering containing keratinocytes (stratified, squamous, epithelial cells that comprise 
skin and mucosa [2]) migrates across the wound surface and undergoes stratification and 
differentiation to reconstitute the barrier function [3].  Epidermal cells from skin 
appendages undergo a phenotypic alteration while removing clotted blood and damaged 
stroma from the wound space [1].  Changes include retraction of intracellular 
tonofilaments, dissolution of intracellular desmosomes, and formation of peripheral 
cytoplasmic actin filaments, which allow cell movement [1].  Dermal and epidermal cells 
no longer adhere to one another due to the cleavage of hemidesmosomal links between 
the epidermis and basal membrane, enabling the lateral movement of epidermal cells.  
Expression of epidermal cell integrin receptors induces interaction with ECM proteins, 
including fibronectin, and vitronectin, that are interspersed with stromal type I collagen at 
the edge of the wound and interwoven with the fibrin clot [1].  The migrating epidermal 
cells dissect the wound, separating desiccated eschar (dead tissue) from viable tissue.  
Migration may proceed between the collagenous dermis and the fibrin eschar once ECM 
degradation has ensued.  
The structural molecules of the provisional ECM contribute to the formation of 
new stroma, referred to as granulation tissue, by providing a scaffold or conduit for cell 
migration. These molecules include fibrin, fibronectin, and hyaluronic acid [1].  After 
migrating into the wound, fibroblasts initiate the synthesis of ECM, as the provisional 
matrix is gradually replaced with a collagenous matrix.  Once an abundant collagen 
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matrix has been deposited in the wound and a keratinocyte monolayer has formed over 
the wound surface, proliferative and synthetic activities subside, migration ceases, and 
differentiation and stratification helps to establish a new epidermis with a basal lamina 
[3].  The fibroblasts stop producing collagen, and the fibroblast-rich granulation tissue is 
replaced by a relatively acellular scar [1].     
The formation of new blood vessels is necessary to sustain the newly formed 
granulation tissue. Angiogenesis refers to the formation of new blood vessels which 
reconstitutes the blood supply to the wound to deliver oxygen and other nutrients.  Vessel 
formation and growth is stimulated by various growth factors (e.g. PDGF, TGF,) 
secreted by activated macrophages and keratinocytes [2].  Proliferating endothelial cells 
secrete proteinases that lyse collagen and other structural proteins to enable their 
migration into the wound and their subsequent deposition of fibronectin into the vessel 
walls to provide scaffolding for further growth.   
During wound contraction, fibroblasts assume a myofibroblast phenotype 
characterized by large bundles of actin-containing microfilaments disposed along the 
cytoplasmic face of the plasma membrane of the cells and by cell–cell and cell–matrix 
linkages [1].  Collagen remodeling during the transition from granulation tissue to scar is 
dependent on continued synthesis and catabolism of collagen at a low rate, but in the 
form of larger bundles with gradually increasing crosslink density.  Collagen remodeling 
and thus ECM reorganization is driven by the epidermal cell production of collagenase as 
well as plasminogen activator, which in turn activates plasmin and collagenase matrix 
metalloproteinase 1 (MMP1).  These enzymes facilitate collagen degradation, ultimately 
enabling remodeling of the ECM as the tear strength of the scar increases over time.     
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Clinical and experimental evidence suggests that diabetic ulcers and other types 
of chronic wounds do not follow an orderly and reliable progression of wound healing.  
Ischemia secondary to vascular disease impedes healing in chronic wounds by reducing 
the supply of oxygen and other nutrients [1].  Tissue oxygenation and blood volume have 
shown to serve as indicators of the wound healing process.  Additionally, studies have 
shown that the inflammatory cells present in wounds consume high amounts of oxygen in 
the production of bacteria-killing oxidants [4]. Plus, angiogenesis, collagen synthesis, and 
epithelialization are all critical processes in wound healing, and each requires a high 
concentration of oxygen [5]. Poor oxygenation and tissue perfusion have previously been 
linked to impaired wound healing [3, 5-7].  Therefore tissue oxygenation and blood 
volume in the wound environment would serve as reliable indicators of wound healing 
progress. 
Hemoglobin is a protein found in blood, comprising a protein globin envelope and 
heme, which blinds and transports oxygen through the use of iron.  Oxygen plays a vital 
role in enzymatic and cellular metabolic reactions necessary for cell growth and 
proliferation.  The greater the hemoglobin level, the greater amount of oxygen may be 
transported to tissues and the greater capacity for wound healing.  Hemoglobins bound to 
oxygen are referred to as oxygenated, and non-oxygen-carrying hemoglobin proteins are 
called deoxygenated.  Previous testing has shown that the rate of change of oxygenated 
hemoglobin concentration in healing wounds is greater than the rate of change in 
deoxygenated hemoglobin concentration [8].  
Increased values of oxygenated hemoglobin would be expected during the late 
inflammatory or early proliferation stages of normal wound healing, as angiogenesis 
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increases the supply of oxygenated blood to the wound.  In the late proliferation stage, 
angiogenesis stops and blood vessels begin to break down as a result of apoptosis [1].  At 
this stage, metabolic activity within the wound bed would correspond to relatively 
constant deoxygenated hemoglobin levels, assuming that an adequate supply of 
oxygenated blood is being delivered to the wound.  This may explain why the changes in 
[Hb] in healing wounds were less pronounced than changes in [Hboxy] observed 
previously [8].  One theory is that chronic diabetic wounds may be stuck in various 
phases of the healing process [4]. The non-healing wounds observed in a previous study 
may have been arrested before reaching the end of the proliferative phase of healing, 
resulting in oxygenated hemoglobin concentrations that were always greater than normal 
tissue and did not decrease like healing wounds [8]. 
 
1.5. Stage of Development [Technology Readiness Level (TRL)] 
 Initial proof of concept 
 Demonstration of technology feasibility 
 First-generation prototype constructively reduced to practice  
These activities correlate to a TRL 3 for the present stage of development for this 
device [9]. 
1.6. Further Development Requirements 
 Continue human clinical trials 
o Expand patient population from the subjects previously investigated in the 
pilot study 
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 IRB has been approved for testing at Temple University pending a 
signed contract 
 Further refine the prototype  
o Develop a non-contact NIR probe using relay lenses to transmit light to 
and from tissue site to access applications and markets beyond the wound 
care segment 
o Incorporate additional optical methods for assessing skin damage and 
healing 
o Optimize comfort, portability and ease of use 
 
1.7. Estimation of R+D Cost 
An important aspect of continued development involves strategic planning vis-à-
vis the associated costs.  The major R+D costs will include conducting an expanded 
clinical study and making refinements to the device prototype.  While these activities 
may be performed concurrently, they will be considered separately in making an 
approximation of the total development cost. 
In expanding the clinical trial, multiple testing centers will likely be necessary in 
order to recruit an adequate number of patients for the study.  This number has been 
determined by analyzing the variability of the data obtained during the pilot study.  An 
unpaired 2-tailed t-test was performed to calculate the sample size using the following 
parameters. 
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 = 0.01;  = 0.1 (Power = 0.9); Mean Diffraction = 6.0; Standard Deviation = 
6.85 
True difference of means (Mean Diff/Std Dev) = 0.87591 
 (Mean dif - SD  / True Diff of Means) = 0.97042   
This calculation assumes that the  values were equivalent for the two sets of data.  The 
output is a sample size for each group, which was set to be equal and then combined to 
give the total sample size.  However, it will not be required that the groups exhibiting 
healing and non-healing wounds be equivalent.  The calculation was performed by using 
these parameter values as inputs for the publicly available sample size calculator tool 
[10].  The sample size returned was: n=38.78767 for each testing group.  This was 
rounded up to 40, yielding a total sample size recommendation of: n=80.  This number of 
patients was incorporated into the following clinical trial model to provide an estimation 
of cost for such a study involving four clinical sites. 
 
 
 
Table 2: Clinical Research Equipment Costs 
 
Equipment Notes Cost 
Lasers $1400 x 2 lasers/device x 4 devices $11,200
Detectors 
$1200 x 2 detectors/device x 4 
devices $9,600
Optical Switch + Daq 
card $3950/device x 4 devices $15,800
PC and software $1500 x 2 PCs/device x 4 devices $12,000
Tegaderm 20 cases x $300/case of 200 $6,000 
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Table 2 (continued) 
 
Misc.  Est. engineering costs $50,000 
  $104,600
 
 
 
 
 
Table 3: Preparation and Execution of the Study 
  
hrs/day
days/ 
that 
month 
Months Number of Sites 
Total 
Hours 
3 month of preplanning  (Coor) 
(plus 1 hr/day PI) 
4 10 3 1 
120 
(+30 
PI) 
2 month of set up (Coor) 8 1.5 2 4 96 
Each month       
 -  Collect weekly data (Coor) 0.5 4 3 4 24 
 - Organize and sort/ enter 
database (Coor) 2 4 3 4 96 
 - Monitor Sites  (Coor) 2 4 3 4 96 
1 close all sites (Coor) 
 (plus 1 hr /day PI) 5 1 1 4 
20 (+4 
of PI) 
3 months analyze data (PI) 
5 10 3 1 
150 
(all 
PI) 
Coor – $45/hr; PI – $115/hr          
Coor: 
452 
PI: 
184 
Coor : $45/hr x 452hr = $20,340 
PI: $115/hr x 184hr = $21,160 
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Table 4: General Estimate of Site Costs 
 
Coor $45 /Hr 
PI $115 /Hr 
O.H. 50 % 
Pat. Reim. $30 /visit
Pat. Reim. 
O.H. 50 % 
 
This budget was based on the numbers above and the following variables: 
‐ Screen-in visit: Coordinator time = 1hr; PI time = 0.5 hr 
‐ Follow up visit: Coordinator time = 1 hr 
‐ Overhead is applied to patient reimbursement 
‐ Total Cost/Site includes  
o One-time Start-Up = $1,000 and IRB Fee = $1,500 
o 1 Screen-in visit plus 24 follow-up visits per patient 
o 20 patients per site 
 
Calculations 
Per Patient Cost $2,920.00 
Per Pat./ per Site $58,400.00 
Total Cost/ per Site $60,900.00 
Cost for All Sites $243,600.00 
 
 
 
Total estimated cost:  $389,700 
        
1.8. Funding Sources 
 U.S. Army Medical Research Acquisition Activity; Cooperative Agreement 
W81XWH 04-1-0419 
 Walter H. Coulter Research Foundation 
 Science Center QED proof-of-concept funding award 
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Chapter 2. Commercialization Potential 
2.1. Market Needs Addressed 
 Currently there is an unmet need to reliably monitor chronic wounds. 
o The ability to accurately assess wound healing would allow for a change 
in the course of therapy long before it becomes clinically obvious. 
o The primary methods physicians have to rely upon are purely subjective, 
involving attempts at three-dimensional measurement and time-stamped 
digital imaging. 
 
2.2. Market Descriptions 
 Market Type:  
o Wound care clinics – mature 
o Wound therapies – emerging 
o Wound assessment – nascent 
o Wound care research – growth  
 Patient Population Dynamics: 
 
 
 
Table 5: Wound Care Addressable Markets [11] 
Type  U.S. Yearly Incidence  
Global Yearly 
Incidence 
Pressure/Decubitus 
Ulcers  2.5 million  9 million 
Venous Ulcers  1.2 million  8 million 
Diabetic/Neutropathic 
Ulcers  2.3 million  20 million  
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 Current Reported Market Size: 
Overall annual cost of Wound Care management = $20 Billion in U.S. [11] 
o Wound care therapies: market segments totaling $5 billion in revenues in 
base year 2008 
 Anti-Infectives 
 Systemic 
 Topical 
 Skin Ulcer Management 
 Compression Dressings and Bandages 
 Wound Cleaners 
 Debridement 
 Moist Dressings 
 Alginates 
 Films 
 Foams 
 Hydrocolloids 
 Hydrogels 
 Negative Pressure Wound Therapy 
 Biological Dressings 
 Artificial Skin 
 Collagen 
 Growth Factors 
 Others 
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 Pressure Relief 
 Miscellaneous Treatments 
 Projected Market Size: $7.3 billion in 2013 
 Market Growth Rate: 8% CAGR over forecast period 2008-2013 
 
2.3. Competitive Landscape: Direct/Indirect Competition 
 Hyperspectral Imaging 
o OxyVu, Hypermed, Inc. [ceased operations as of Nov. 2009] 
 Morphological Evaluation [Digital Photography, Manual Inspection and 
Measurement] 
o Visitrak, Smith and Nephew 
o Silhouette Mobile, Aranz Medical 
o (Film tracing kit), Ferris Corp. 
 Biosensors 
 
2.4. Competitive Landscape: Potential Customers by Segment 
 Wound Clinics: 
o The Association for the Advancement of Wound Care (AAWC) is 
the preeminent multidisciplinary organization for wound care. The AAWC 
Wound Care Clinic Directory is published to help those in need of wound 
care and management to locate sites across the country where healthcare 
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professionals are specifically involved in wound care. It also provides a 
networking guide for professionals to share wound care clinical expertise. 
At this time, over 900 clinics/centers are included from across the US as 
well as other countries. Information available on clinics/centers includes: 
Facility Name, Director/Contact, Address, Phone, Fax, Email, and Type of 
Clinic/Center (whether Hospital-based, Stand-alone/private, Corporate-
affiliated).  Copies of the directory may be obtained online for free to 
AAWC members or for public purchase [www. 
http://www.aawconline.org/storewoundclinicdirectory.shtml], or via the 
AAWC Business Office at: 83 General Warren Blvd.; Suite 100; Malvern, 
PA 19355. 
 
 Wound Healing researchers: 
o This group comprises the academic wound healing research community, 
including investigators at universities and teaching hospitals as well as the 
companies listed below developing new therapies.  These researchers may 
be identified by journal publications, conference proceedings, AAWC 
membership, and grant applications listed in the NIH/NICCR CRISP 
database.   
 
 Wound care therapies:  
o Anti-Infectives 
 Systemic, Topical 
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Table 6: Selected Topical Brand Name Anti-Infectives Currently 
Available [11] 
 
 
 
 
The total worldwide revenues for the skin ulcer treatment anti-infective 
market in 2008 reached revenues of $1.0 billion. The market is projected 
to reach $1.3 billion in 2013, reflecting a compound annual growth rate of 
9.3%. Continued growth for anti-infective to treat skin ulcers is largely 
due to anticipated sales of Zyvox and an increase in skin ulcers due to an 
aging population. 
 
o Skin Ulcer Management 
 Compression Dressings and Bandages 
 
 
 
Product  Active Ingredient  Manufacturer 
Bactroban  Mupirocin  GlaxoSmithKline 
Betadine Brand First Aid 
Antibiotics + Moisturizer 
Ointment 
Bacitracin zinc, 
polymyxin B sulfate Purdue Fredrick 
Clorapactin WCD-90  Oxychloroscene  Guardian 
Critic-Aid AF  miconazole  Coloplast 
MetroGel  Metronidazole  Galderma 
Mycostatin  Nystatin  Bristol-Myers Squibb 
Neosporin  Neomycin sulfate  Pfizer 
Silvadene  Silver sulfadiazine  King Pharmaceuticals 
Sulfamylon  Mafenide acetate  Mylan 
Terramycin  
Oxtetrcycline, 
polymyxin B sulfate Pfizer 
Thermazene Cream  Silver sufadiazine  Kendell/Covidien 
Zyvox  Linezolid  Pfizer 
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Table 7: Selected Compression and Composite Dressings and 
Bandages Currently on the Market [11] 
 
Manufacturer  Products  
3M  Coban, Tegaderm Plus  
ACI Medical  ArtAssist  
Aircast  
ArterialFlow System, EdemaFlow System, VenaFlow 
System  
Avcor Health Care  Honeycomb X-ten, X-Econ, Adban  
Products   
Beiersdorf-Jobst  Gelocast Unna Boot  
BioMed Sciences  Silon  
Coloplast  CircPlus, CircAid TheraBoot  
ConvaTec  
DuoDerm, Setopress, SurePress, Turbigrip, 
UnnaFlex,  
DermaSciences  Mobility1  
DeRoyal  CovaDerm  
Hartmann-Conco  
Fourpress, ThreePress , LoPress, CoLastic, E-Paste 
Unna Boot, Unna Boot with Colamine  
Hollister  HeelBoot  
Johnson & Johnson  Dyna-Flex  
Kendall  Tenderwrap, Viasorb  
Medline  Four Flex, Stratasorb Composite  
Molnlycke  Mepilex, Mepitel, Mepilex Border, Alldress  
MPM  MPM  
Smith & Nephew  Profore, OpSite Post-op, Exu-Dry  
Western Medical  Primer Unna Boot  
 
 
 
 Debridement 
 Autolytic debridement, Biotherapy ( maggot therapy), 
Enzymatic debridement, Mechanical (hydrotherapy, wet-to-
dry and wet-to-moist dressings, low frequency ultrasound), 
Sharp debridement or surgical debridement (including laser 
debridement) 
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Table 8: Selected Debridement Agents [11] 
 
Manufacturer  Product  
Cooper Surgical  Irrijet DS  
Davol  
Simpluse VariCare Pulsed Lavage System with 
Suction System  
DeRoyal  Jetox  
Ethex  Ethezyme  
Healthpoint  Accuzyme, Panafil  
Johnson & Johnson  Debrisan  
Mylan  Granulex, Proderm  
Ross Products  Collagenase Santyl  
Smith & Nephew  Gladase, Versajet  
Soring  Sonoca 180  
Stratus Pharmaceuticals  Kovia Ointment, Ziox Ointment  
UDL  Granulex  
 
 
 
 Wound Cleansers 
 Non-antimicrobial, Anti-bacterial 
 
 
 
Table 9: Selected Cleansing Agents Currently on the Market [11] 
 
Manufacturer  Product  
3M  Cavilon  
Anacapa Technologies  Anasept  
AstraZeneca  Hibiclens  
Bard  Bard Wound Cleanser, Biolex  
Blairex  Wound Wash  
Care-Tech  Clinical Care, Techni-Care Scrub  
Carrington Laboratories  Cara Klenz, Ultra Klenz  
Coloplast  Sea-Clens  
ConvaTec  Saf Clens  
DermaRite  DermaKlenz  
DermaSciences  Dermagran  
Healthpoint  ALLCLENZ  
Hollister  Restore  
Hyperion Medical  Hyperion  
Ivory  Ivory Soap  
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Table 9 (continued) 
 
Kendall  Constant Clens  
Medline  Sureprep  
Molnlyke  Hypergel  
MPM  MPM  
Purdue Frederick  Betadine Surgical Scrub  
Sage  Comfort Shield  
Smith & Nephew  Iodoflex , Iodosorb  
Stratus Pharmaceuticals  Peviderm  
Swiss American  Elta Dermal  
Winchester Laboratories Salijet  
 
 
 
The skin ulcer management products market achieved revenues of $241.2 
million in 2008 and is projected to grow at a compound annual rate of 
4.7%, reaching $302.9 million in 2013. Driving growth is the rising 
number of skin ulcers resulting from an increasing diabetic population. As 
the population ages, the number of people diagnosed with diabetes 
increases, resulting in an increase in diabetic ulcers. In 2008, the largest 
subsegment within the worldwide skin ulcer management market was 
debridement products followed by compression bandages and dressings 
with revenues estimated at $115.1 million and $97.3 million, respectively. 
o Moist Dressings 
 Alginates 
 
 
 
Table 10: Selected Alginate Products Currently on the Market 
[11] 
 
Manufacturer  Product  
3M Health Care  Tegagen HG, Tegagen HI, Tegaderm Alginate 
Advanced Medical Solutions ActivHeal Alginate, ActivHeal Aquafiber  
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Table 10 (continued) 
Argentum  Silverlon CA  
B Braun  FyBron  
Bard  Algiderm  
Carrington  Crrasorb II, Carriginate  
Coloplast  SeaSorb  
ConvaTec  Kaltostat, Aquacel, Carboflex  
Derma Sciences  
DermaStat Calcium Alginate Wound Dressing, 
Algicell Ag, MediHoney Calcium Alginate  
DeRoyal  Kalginate, Algidex, Dermanet Ag+  
Dow Hickam  Sorbsan  
Ferris Mfg.  PolyMem  
Gentell  Gentell Calcium Alginate Dressing  
Hartmann-Conco  Sorbalgon  
Hollister  Restore  
Invacare  Invacare Calcium Alginate Dressing  
Johnson & Johnson  Algosteril, Silvercel, NU-DERM, Alginate  
Kendall  Curasorb, Curasorb Zinc,  
Lohmann-Rauscher  SupraSorb A  
Medline  Maxorb, Maxsorb Ag  
Molnlycke  Melgisorb  
MPM  Excelginate  
Smith & Nephew  AlgiSite, Acticoat Absorbant  
Unomedical  Sorbsan Alginate Dressing, Sorbsan Silver  
 
 
 
 Films 
 
 
 
Table 11: Selected Films and Composites Currently on the Market 
[11] 
 
Manufacturer  Product  
3M  
Cavilon, Tegaderm HP, Tegaderm, Tegaderm Absorbent 
Clear Acrylic Dressing, Tegaderm Matrix with PHI  
Advanced Medical 
Solutions ActivHeal Film  
Beiersdorf  Coverlet Adhesive Dressing, Cutifilm Plus  
BioMed Sciences  Silon TSR  
Carrington  CarraFilm  
Coloplast  Coloplast Film  
DermaRite Industries  DermaView  
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Table 11 (continued) 
DeRoyal  Transeal, Covaderm Plus  
Gentell  Gentell’s Covertell Layered Dressing  
Global Health 
Products  Defend Film Dressing  
Hartmann  Hydrofilm, Sorbalux  
Invacare Supply 
Group  Invacare Transparent Film Dressing  
Johnson & Johnson  Bioclusive MVP, Bioclusive  
Kendall  
Polyskin II, Polyskin M.R., Blisterfilm, Telfa Plus 
Barrier Island Dressing, Telfa Xtra Absorbant Island 
Dressing, Ventex Wound Dressing  
Medline  SureSite  
Molnlycke  Mepore (formerly Mefilm)  
Smith & Nephew  OpSite Flexigrid, OpSite  
TriState Hospital 
Supply  Centurion SiteGuard, Centurion SiteGuard MVP  
Unomedical  C-View Film Dressing  
 
 
 
 Foams 
 
 
 
Table 12: Selected Foam and Composite Manufacturers [11] 
 
Manufacturer  Product  
3M  Reston, Tegaderm Foam  
Advanced Medical Solutions ActivHeal Foam Dressings  
Bio Med Sciences  Silon Dual-Dress  
Carrington  CarraSmart, CarraFoam  
Coloplast  Biatain Foam, Contreet Adhesive Foam  
ConvaTec  
 Carboflex, Versiva, Versiva XC Gelling Foam, 
with Hydrofiber Technology  
DermaSciences  Foam Dressings  
DeRoyal  Polyderm, Algidex Ag  
Ferris  
PolymemSilver, Polywic, Polywic Silver, 
Polymax, Polymem Ag  
Gentell  LoProfile Foam and Foam Plus Dressings  
Global Health Products  Medifoam Island Dressing  
Hartmann-Conco  PermaFoam, PermaFoam Island  
Hollister  Restore Foam  
Hydrofera  Hydrofera Blue  
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Table 12 (continued) 
 
Invacare Supply Group  Invacare Foam Island Dressing  
Johnson & Johnson  Tielle, BioPatch, Sof-Foam  
Kendall  Hydrasorb, Curafoam, COPA, COPA Plus  
Lendell Mfg  Microbisan  
Medline  Gentle Heal, Optifoam, Optifoam Ag  
MoInlycke  
Mepilex, Mepilex Lite, Lyofoam, Lyofoam A, 
Lyoform C, Lyoform Extra, Lyofoam T 
Smith & Nephew  Allevyn, Acticoat Foam Dressing  
UDL Labs  Flexzan Foam Dressing  
Unomedical  Foam Dressings, Trufoam  
 
 
 
 Hydrocolloids 
 
 
 
Table 13: Selected Hydrocolloid Products Currently on the 
Market [11] 
 
Manufacturer  Product  
3M  TegaSorb, TegaSorb THIN  
Advanced Medical Solutions ActivHeal Hydrocolloid  
B. Braun  Askina Hydrocolloid  
Coloplast  
Comfeel, Triad, Coloplast Plus, Granuflex 
Hydrocolloid  
ConvaTec  
CombiDerm ACD, DuoDerm CGF, DuoDerm, 
SignaDress Sterile, Contreet  
DermaRite  DermaFilm HD  
DermaSciences  
Primacol Hydrocolloid, MediHoney 
Honeycolloid  
DeRoyal  ProCol  
Gentell  Dermatell, Dermatell Secure  
Hartmann-Conco  Flexicol  
Hollister  Restore, Restore CX, Sacram  
Invacare Supply Group Hydrocolloid Dressings  
Johnson & Johnson  Nu-Derm  
Kendall  Ultec Pro  
Medline  Exuderm Satin  
Smith & Nephew   Replicare  
Spenco  PrimSkin Hydrocolloid  
UDL  Hydrocol II  
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 Hydrogels 
 
 
 
Table 14: Selected Hydrogel Products Currently on the Market 
[11] 
 
Manufacturer  Product  
3M  Tegagel  
Advanced Medical Solutions ActivHeal Hydrogel  
Amerx  Amerigel  
Anacapa Technologies  
Silver Shield Silber Antimicrobial Skin and 
Wound Gel  
B. Braun  Hyfil, ThinSite Transorbent  
Bard  Biolex, Vigilon  
Carrington  
CarraGauze, CarraSorb, Carrasyn, DiaB Gel, 
RadiaCare Gel, Carradress  
Coloplast  Purilon Gel, WounDres, Biatain  
ConvaTec  
SAF-Gel Hydrating Wound Dressing, 
DuoDerm Hydroactive Gel  
DeRoyal  AquaGauze, MultiDex Powder/Gel  
DermaRite  DermaSyn  
DermaSciences  Dermagran, NutraFill, NutraVue  
Geistlich Pharma  Geliperm  
Gentell  Gentell Hydrogel  
Hartmann  Hydrogel Sheet Dressings, Hydrosorb  
Healthpoint  Curasol Gel  
Horizon Medical  SteriCare  
Hyperion Medical  Hyperion Hydrophilic Gel  
Johnson & Johnson Nugel  
Kendall  Curafil, Kendall Cold Wrap, Curagel  
Meditech International  Spand Gel  
Medline Industries  
SkinTegrity, DermaGel, SilvaSorb Gel, 
Tenderwet, X-cell, Silvasorb, Silver Hydro,  
Molnlycke  Hypergel, Normgel  
MPM  
MPM Conductive Gel Pad, MPM GelPad, 
Hydrogel Pad, Cool Magic, Excel Gel, 
SilverMed, Regenecare  
Orion  OriGel  
Smith & Nephew  TransiGel, SoloSite, IntraSite, Aquafor  
Southwest Technologies  Elasto-Gel, Elasto-Gel Plus  
Spenco  PrimSkin Hydrogel  
Swiss-American Products  Elta Dermal  
Unomedical  Aquaform  
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Table 14 (continued)  
 
XCELLentis (Celltran)  UlcoDress Plus  
X-Static  SilverSeal  
Xylos  X-Gel  
 
 
 
The moist dressing market achieved revenues of $315.4 million in 2008 
and is projected to grow at a compound annual rate of 6.1%, reaching 
$424.8 million in 2013. Growth in the moist dressing segment is fueled by 
the development of antimicrobial dressings which contain silver and other 
antimicrobial products. Areas such as alginates will show strong growth 
due to the continued introduction of combination products with 
antimicrobial properties. In 2008, the largest subsegment within the 
worldwide skin ulcer moist dressing market was hydrocolloids in terms of 
total revenues. Hydrocolloids account for approximately 37% of total sales 
with $117.6 million in sales for 2008. The second largest category was 
films followed by alginates with $81.4 million and $45.1 million, 
respectively. 
 
o Negative Pressure Wound Therapy 
 
 
 
Table 15: Selected Negative Pressure Wound Therapy Products 
Currently on the Market [11] 
 
Manufacturer  Product  
Smith & Nephew  Versatile 1, V1STA  
Boehringer Wound Systems  Engenex  
KCI  VAC  
Medela  Invia Healing System  
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The negative pressure wound therapy market achieved revenues of 
$1,080.1 million in 2008 and is projected to grow at a compound annual 
rate of 12.2%, reaching $1.9 billion in 2011. Growth is primarily fueled by 
an increased acceptance of NPWT products and new approvals. The 
leading provider of NPWT is Kinetic Concepts who generates more than 
$1 billion in sales alone. Kinetic Concepts reported growth in the 
United States was attributed to higher average units on rent and an 
increase in sales volumes for V.A.C. disposables. Internationally, V.A.C. 
revenues were supported by increase in product demand and a steady 
rental price. Increases were also noted for growth of V.A.C. disposables 
internationally. 
o Biological Dressings 
 Artificial Skin 
 
 
 
Table 16: Selected Artificial Skin Products Currently on the Market 
[11] 
 
Manufacturer  Product  
Advanced Bioheal  Dermagraft, Transcyte  
Bristol-Myers Squibb  VivaDerm  
CytoMedix  Autologel (on hold)  
Genzyme  EpiCel  
Healthpoint  Oasis  
Integra  Integra Bilayer Matrix  
Johnson & Johnson Regranex  
Lifecell  Alloderm  
Organogenesis  Apligraf  
Ortec  OrCel  
Promethean LifeSciences  GammaGraft  
TEI Biosciences  PriMatrix  
Wright Medical  GraftJacket  
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 Collagen 
 
 
 
Table 17: Selected Collagen Products Currently on the Market [11] 
 
Manufacturer  Product  
Argentum  BioPad  
BioCore  Medifil, SkinTemp  
Brennen  BGC Matrix  
Celgene  Biovance  
Collagen Matrix  Matrix Collagen Sponge Wound Dressing, 
Matrix Collagen Film Wound Dressing  
Coloplast Sween  WounDress  
Derma Rite  Collagen Ag  
Johnson & Johnson  Fibracol , NuGel, Promogran, Prisma  
Medline  Puracol, Medifil Particles  
Molnlycke  Mepore Pro  
Smith & Nephew  ColActive  
Southwest Technologies Stimulen  
TEI Biosciences  DressSkin  
The Hymed Group  HyCure Smart Gel  
Wound Care Innovations  Cellerate Gel/Powder  
 
 
 
 Growth Factors 
Each of the four major families of angiogenic growth factors can induce soft 
tissue vascularization and promote healing. Topical therapies have evolved from 
the interactive stimulation of the wound through the use of growth factors. 
Growth factors are a large and diverse group of peptides that coordinate all 
aspects of interactions between cells. They are signal proteins released from local 
tissues or blood products that activate target cells to replicate or migrate. 
Growth factors are members of the cytokine family, which includes interleukins 
and colony-stimulating factors. They may be named according to their function, 
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cell origin, or the target cell toward which their action is directed. The presence or 
absence of growth factors significantly influences the wound closure process. 
There are five major growth factor categories that contribute to the wound healing 
process: 
• Epidermal growth factor (EGF) – induces epithelial development and promote 
angiogenesis 
• Transforming growth factor beta (TGF-beta) – increases the chemotaxis and 
mitosis of osteoblasts precursors and they also stimulate osteoblasts deposition of 
the collagen matrix of wound healing and bone regeneration. 
• Fibroblast growth factor (aFGF and bFGF) 
• Insulin growth factor (IGF-I and IGF-II) 
• Platelet-derived growth factor. (PDGF) – initiates connective tissue healing 
including bone regeneration and repair. PDGF also increases mitogenesis, 
angiogenesis, and macrophage activation of the wound site and second phase 
source of growth factors 
Growth factors can be produced outside the body by two methods. The first 
entails centrifuging blood to isolate platelets and then adding thrombin (e.g. 
platelet-derived wound healing formula). This produces a crude preparation with 
uncertain concentrations of different growth factors. The second method uses 
recombinant techniques to isolate the gene that produces a specific growth factor 
protein. The gene is used to create a purified quantity of a single type of growth 
factor, for example, basic fibroblast growth factor (BFGF), epidermal growth 
factor (EGF) and platelet-derived growth factor (PDGF). Another example of a 
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growth factor used in wound healing is placental angiogenic growth factors 
(PGFs). This growth factor preparation is applied as a topical salve, and 
reportedly stimulates the regrowth of soft tissue, capillaries, and skin. 
There are many types of growth factors; however, only platelet-derived 
growth factors have been approved by the FDA for use in wound care. Platelet 
alpha granules contain potent growth factors necessary to begin tissue repair and 
regeneration at the wound site. Concentrated autologous platelets present huge 
reservoirs of growth factors that have the potential to greatly accelerate the 
normal healing process, naturally. The use of concentrated growth factors is 
considered by many to be a “new frontier” of clinical An example of a 
recombinant human platelet-derived growth factor is Regranex offered by 
Chiron/OrthoMcNeil. Regranex is a topical genetically-engineered gel to treat 
deep diabetic foot and leg ulcers. Becaplermin is produced through recombinant 
DNA technology by inserting the gene for the B chain of platelet-derived growth 
factor into a yeast called Saccharomyces cerevisiae. Chiron produces the 
concentrated becaplermin and supplies it to Ortho-McNeil. 
 
 Others 
Integra LifeSciences recently launched the Integra Bilayer Matrix Wound 
Dressing for advanced wound care. The product is a two-layer tissue-engineered 
matrix, which is part of a family of products that includes the Integra Dermal 
Regeneration Template. The outer layer is made of a thin semipermeable silicone 
film that acts as the skin’s epidermis. 
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It protects the wound from infection and controls both heat and moisture loss. 
The inner layer is constructed of a complex biodegradable matrix of cross-linked 
fibers. This porous material provides a scaffold for cellular invasion and capillary 
growth. The scaffold is eventally remodeled as the patient’s cells rebuild the 
damaged site. The product provides immediate wound coverage, is highly 
comformable for various anatomical sites, and offers excellent performance in 
deep donor sites. Wright Medical offers GraftJacket Ulcer Repair Matrix, which 
is designed to allow healing at deeper levels, while protecting the external layer of 
the wound with a graft material that converts into functional host tissue. 
The biological dressings market achieved revenues of $550.5 million in 
2008 and is projected to grow at a compound annual rate of 9.8%, reaching 
$880.0 million in 2013. Growth is supported by advancing technologies and 
an increased presence for biological products internationally. Market 
expansions have become intense in many European and Asian regions. 
Additionally, higher priced products have continued to show high demand in 
recent years. In 2008, the largest subsegment within the worldwide biological 
dressing market was growth factor products in terms of total revenues with 
$421.1 million in sales for 2008. This represents 76.4% of the total biological 
dressing market. The second largest category was other biological dressings, 
followed by collagen and artificial skin. Sales for artifical skin represent the 
fastest growing segment in the biological dressing market with 16.1% growth 
compounded annually from 2003 to 2013. 
 
o Pressure Relief 
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Pressure relief equipment is designed to prevent pressure ulcers from 
occurring or to facilitate healing of existing pressure ulcers. Two overall concepts 
as such are in place for pressure relief therapy systems. The market offers either 
static system (non electric) or active dynamic systems (electric).  
 
Table 18: Selected Pressure Relief Equipment Currently Available on the 
Market [11] 
 
 
 
Manufacturer  Product  
AirCare Therapy, Inc.  Bari-SelectAir Low Air Loss System  
American Health  
UltraForm IST Therapeutic Mattress, Overlay, 
X-ception  
Systems  Bariatric Mattress  
BG North America 
(Encompass Group)  
AccuMax Quantum Mattress, MariFlex, 
MaxiFloat, Optimax Mattress  
Bio Clinic  
EggCrate convoluted overlays, flat foam 
overlays, ProAire  
Crown Therapeutics  
Prodigy Mattress System, Sofflex Mattress 
System  
DM Systems  
Elbowlift, Heelift, Heelift Bariatric Suspension 
Boot, Heelift Petite Suspension Boot  
EHOB  Waffle Overlay  
Gaymar Industries, Inc  
Clini-Float Flotation Therapy Bed System, Sof 
Care, XRPT Pulmonary Mattress, Plexus 
Products, Isoflex with Silver 3, SPR Plus III, 
Symmetric Aire  
Geritex  Angel Mattress System  
GF Health Products  
Lumex Altadyne 5 Alternating Pressure/Low 
Air Loss System  
Grant Airmass  Dyna-Care, Dyna Soft  
Hill Labs  Adjustable 90W  
Hill-Rom  
Acucair, Clinitron line, Comfortline, Flexicair, 
MC3, Flexicair, Eclipse, ExCel Care, TotalCare 
Bariatric, Magnum Bariatric, CareAssist, 
Synergy, ZoneAire, PrimeAire   
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Table 18 (continued) 
 
KCI  
BariAir Therapy System, BariKare, Fluid Air 
Elite, Fluid Air II, Fluid Air HC, KinAir III, 
KinAir IV, Maxxis 300, Maxxis, 400, 
PediDyne, Roto Rest Delta, Therapulse, 
Therapulse II, TriaDyne II, Totalcare Bariatric 
Plus, BariMax  
KCI  
DynaPulse, FirstStep, TriaDyne, MaxxAir, 
AirMaxxis, RotoProne therapy, Plexipulse, 
AtmosAir  
Medline  
Odessey, Prevent, Medtech 800, Q-Star 
Voyager, Nylex II  
Sten + Barr Medical  Body Float, Symmetric Aire  
Sage  Prevalon Heel Protector  
SAM Medical  Bursa Med  
Spenco  Contrax, Improtec ST, Comfi-med  
TEK Scan  Conform Mattress System  
Tempur Pedic Medical 
Divison  Tempur-Med Mattress  
Tri-Line Medical  Bari-10A, ProCair One, ProCair Two  
Winco  LiquiCell Chairs  
 
 
 
The pressure relief skin ulcer products market achieved revenues of 
$1.5 billion in 2008 and is projected to grow at a compound annual rate of 
5.8%, reaching $2.0 billion in 2013. Growth is supported by new 
developments for specific populations, particularly products to 
accommodate the rising obesity in developed regions such as the United 
States and Europe. Products which address the needs of the growing obese 
and elderly populations will likely succeed in top product sales throughout 
the forecast period. 
 
o Miscellaneous Treatments 
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 Electrical Stimulation 
Electrical stimulation physical therapy uses an electrical current to transfer 
energy to a wound, which is regulated by an electrical source. Capacitatively 
coupled electrical stimulation involves the transfer of electric current through an 
applied surface electrode pad that is in wet contact with the external skin surface 
and /or wound bed. When 
capacitatively coupled electrical stimulation is used, two electrodes are required 
to complete the electric circuit. Electrodes are usually placed over wet conductive 
medium, in the wound bed and on the skin a distance away from the wound. 
Biofisica offers an innovative product, the Posifect RD Bio-electric simulation 
therapy The Posifect RD Bio-electric stimulation therapy is a disposable one-time 
use dressing that was launched in Europe. 
 
 Electromagnetic Therapy 
Ivivi Technologies offers an innovative product, the SofPulse T, a non-
invasive device for treating pain and edema in soft tissue in treatment of chronic 
wounds. The SofPulse T is a pulsed electromagnetic therapy device that delivers 
therapy directly through dressings, casts or clothing without touching the skin. 
 
 Ultraviolet 
Ultraviolet wound healing devices are used primarily to eliminate bacteria, 
since the UV rays are known to kill bacteria. Hand-held devices provide the 
application of UV rays to the wound but outcomes for this device have been only 
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randomly reported. Therefore, there has been little research done on this method 
of wound healing. There are currently two companies involved in the manufacture 
and distribution of UV products for wound healing: Medfaxx and American 
Ultraviolet Company. 
 
 Oxygen and Hyperbaric Oxygen 
Oxygen is essential for maintaining cellular integrity, function, and repair 
when tissues are injured. Oxygen not only plays an important role in energy 
metabolism, but also is very important in polymorphonuclear cell function, 
neovascularization, fibroblast proliferation, and collagen deposition. As healing 
progresses, new granulation tissue that is exposed to hyperbaric oxygen is better 
vascularized. This in turn leads to higher tensile strength collagen being formed 
during wound healing, which reduces scarring and the risk of recidivism. Larger 
wounds may have significantly increased metabolic demands, and larger areas of 
compromised microvascular oxygen delivery limiting the healing process. 
Hyperbaric oxygenation (HBO) is defined as 100 percent oxygen delivered at 
an atmospheric pressure greater than ambient pressure. The goal of hyperbaric 
oxygenation is to enhance oxygen levels in wound tissue. Increased tissue oxygen 
has been shown to increase fibroblast proliferation and production of collagen, to 
enhance angiogenesis, and to facilitate oxidative killing of bacteria by phagocytic 
cells as well as having a direct effect on anaerobes. 
HBO can be delivered systemically or topically. Systemic delivery is achieved 
through the use of a monoplace chamber (room for one patient only, pressurized 
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with oxygen, patient breathes normally) or a multiplace chamber (room for 
multiple patients, pressurized with air, patients breathe oxygen through a mask) 
pressurized at 2 to 3 times ambient atmospheric pressure. In this method, the 
plasma of the systemic circulation is super-oxygenated and the oxygen is 
delivered to the wound tissues by way of the dermal vasculature and diffusion. 
Topical delivery of hyperbaric oxygen is achieved via a sleeve that encases the 
patient's limb, which is then pressurized slightly more than one atmosphere. The 
oxygen inside the sleeve is then absorbed into the wound tissue and fluids 
directly. There is controversy as to the depth of absorption of topical oxygen and 
therefore the depth of its effect. However it is believed to enhance superficial 
bacterial control by phagocytes as well as epithelization. A recent Israeli clinical 
trial used topical HBO in combination with low energy laser to augment 
conventional therapy in 50 patients with diabetic foot ulcers and reported that 43 
of the ulcers closed in an average of 3 months. It is difficult to separate the effect 
of the topical oxygen from that of the low energy laser in this study as topical 
oxygen alone was utilized in only 15 of the patients. 
The difference between systemic HBO and topical hyperbaric oxygen 
(THBO) in therapeutic approach is that systemic HBO increases blood oxygen 
levels. However, blood oxygen levels are normally adequate for wound healing. 
The problem is that oxygen delivery to the wound site can be limited by poor 
wound tissue vascularization. Topical hyperbaric oxygen on the other hand 
delivers oxygen directly to the wound. 
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Transcutaneous oxygen levels are increased, despite the lack of well 
vascularized wound tissue. In addition, because this therapy is topical and 
relatively low pressure, there is no systemic absorption of oxygen, and therefore 
no risk of pulmonary or central nervous system toxicity that can result from 
breathing high pressure (30—45 psi) oxygen in full body chambers. GWR 
Medical manufactures a Topical Hyperbaric Oxygen device that is applied 
directly to the base of an open wound at pressure slightly above atmospheric e.g. 
1.03 atmospheres (22 mm Hg or 0.4 psi.). The product is disposable and is 
designed to be used one time and discarded. Hyperbaric Technologies offers a 
wide variety of hyperbaric systems. The company is part of the OxyHeal Health 
Group that manages training, manufacturing and hyperbaric chambers. Other 
companies that offer hyperbaric units include Pan-America Hyperbarics, Seachrist 
Industries and Perry Baromedical. Ogenix Corporation introduced EpiFLO, which 
provides continuous transdermal, sustained oxygen therapy. 
Oxygenesys TDO by Acrymed is an innovative wound healing process. In the 
process sufficient oxygen penetrates deep into tissues to make up for the oxygen 
deficiency that may be encountered in chronic wounds. The results show that this 
new technology delivers significant amounts of oxygen to the wound site and 
even permeates the skin tissue at a rate that is at least 3 times higher than the level 
delivered by blood. The product is still under investigation. Insense offers the 
Oxyzyme wound dressings that are as easy to use as conventional dressings, are 
comfortable for the patient, and provide oxygen balance where it is needed most. 
Achimed, the wound healing division of Insense, launched the product in May 
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2007. A second product offered by Achimed is Iodoyme. Iodoyme is the same as 
Oxyzyme but has the added benefit of broad spectrum anti-microbial dressing of 
increased effectiveness and duration. The product is expected to be available in 
late 2007. O2Misly offered by IYIA Technologies is a new method, a medical 
device that offers a combination, adjunctive therapy to the standard of care. 
O2Misly provides oxygen infused under micro tension in a closed chamber 
blended with a mist, which also delivers an antimicrobial to the affected area. The 
product is producing good results with diabetic foot ulcers that have been chronic. 
 
 Whirlpool Therapy 
Whirlpool therapy is used once or twice daily for about 20 minutes during the 
inflammatory stage of healing to enhance circulation and bring more oxygen into 
the wound area. The whirlpool also softens and loosens dead tissue and cleanses 
the wound. Some patients find that whirlpool therapy relieves wound pain. 
Whirlpool therapy should not be used on wounds that are in the proliferative stage 
of healing because it will damage the fragile skin cells, nor should it be used on 
venous ulcers, which result from too much blood in the area. An example of a 
whirlpool would be Ferno Ille Whirlpools. 
 
 Ultrasound 
Celleration offers its therapeutic ultrasound platform. The patented MIST 
Technology utilizes ultrasonic sound waves to produce an energized mist of 
sterile saline in a noncontact fashion. Longport offers the Episcan I-200, which 
 
 
37
allows for noninvasive imaging of the skin and underlying soft tissue. This 
provides clinicians with objective identification of deep tissue injury for improved 
wound assessment as well as early, more reliable detection and prevention of 
pressure ulcers. 
 
 Low Intensity Laser Therapy 
Meditech International offers the Bioflex Low Intensity Laser Therapy 
system. The Bioflex system is currently the most advanced low intensity laser 
system available for the treatment of venous and atherosclerotic ulcers. Medical 
Quant offers the TerraQuant System. This is a unique device that delivers four 
different modalities in one system: red light, infrared light, laser light and 
magnetic. Pulsed red light is identified with beneficial anti-inflammatory effects 
(especially in areola tissue). Theralase offers the T-1000, which is one of the most 
powerful low intensity laser light (LILT) units approved by the FDA. The device 
is a super-pulsed 905 nm Near Infrared (NIR) laser diode technology delivering 
peak powers of up to 50,000 mW for greater depth of penetration and bio-
activation at tissue depth with average power up to 100 mW. It also combines a 
visible red 660 nm laser diode technology offering average powers up to 25 mW, 
allowing for optimal surface stimulation. 
The Wound Care Laser offered by biolitec is a 930nm gallium aluminum-
arsenide diode laser that is designed for management of neuropathic foot and leg 
ulcers of patients with diabetes. The 11-pound laser, which has an integrated 
computer, has been cleared for the debridement of wounds. The miscellaneous 
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skin ulcer treatment market achieved revenues of $278.1 million in 2008 and is 
projected to grow at a compound annual rate of 8.1%, reaching $410.2 million in 
2013. Growth reflects new developments and a growing use of alternative 
treatments for treatment of difficult to heal wounds. 
 
2.5. Barriers to Entry 
 FDA approval is required, but the technology may be able to obtain a 510k 
clearance. 
 Initially, it may be difficult for this robust device to establish traction in a market 
filled with low-cost alternatives, many of which are single-use disposables. 
o Clinicians could be slow to adopt if they see the device as over-
complicated 
o The medical reimbursement paradigm is presently unclear. 
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Chapter 3. Intellectual Property Landscape 
3.1. Type of Patent  
 Foundational Patent 
o This patent may serve as a base patent for a larger family of patents 
(foundational patent). 
o This patent is not based on earlier work covered by Drexel patents (not a 
derivative patent). 
 
3.2. Potentially Relevant Art 
 
 
 
Table 19: Listing of Patent References of Possible Relevance 
 
Reference Title Assignee 
US 20060155193 Visible-near infrared spectroscopy in 
burn injury assessment 
National Research 
Center of Canada 
WO 2007144817 Skin monitoring device, method of 
monitoring the skin, monitoring device, 
method of irradiating the skin, and use of 
an OLED 
KONINKL 
PHILIPS 
ELECTRONICS 
NV and inventors 
US 20050273011 Multispectral imaging for quantitative 
contrast of functional and structural 
features of layers inside optically dense 
media such as tissue 
Inventors of the 
particular 
technology 
US 20030139667 Tissue viability/health monitor utilizing 
near infrared spectroscopy 
Inventors of the 
particular 
technology 
US 20070038042 Hyperspectral technology for assessing 
and treating diabetic foot and tissue 
disease 
HyperMed, Inc. 
US 20070249913 Hyperspectral Imaging of Angiogenesis HyperMed, Inc. 
US 20070232930 Hyperspectral Imaging in Diabetes and 
Peripheral Vascular Disease 
HyperMed, Inc. 
US 6,640,130 Integrated imaging apparatus HyperMed, Inc. 
WO 0103050 IMAGING APPARATUS WITH 
MEANS FOR FUSING THERMAL 
AND HYPERSPECTRAL IMAGES 
HyperMed, Inc. 
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 Table 19 (continued) 
 
US 20020173723 Dual imaging apparatus HyperMed, Inc. 
WO2009117603A2  MINIATURIZED MULTI-SPECTRAL 
IMAGER FOR REAL-TIME TISSUE 
OXYGENATION MEASUREMENT 
HyperMed, Inc 
US 20060052678 Monitoring platform for wound and ulcer monitoring and detection PhiloMetron 
US 7,046,832 Imaging of scattering media using relative detector values 
The Research 
Foundation of 
State Univ. of 
New York 
 
 
 
3.3. Patent Landscape Analysis 
Landscaping was performed using the Thomson Innovation patent intelligence 
software suite.  To date, only 1st generation citing patents were included in the 
analysis, of which the assignees are provided below.  
 Universities, Research Foundations and Hospitals in IP Space 
o Drexel University 
o Duquesne University of the Holy Spirit 
o Wisconsin Alumni Research Foundation 
 Corporations in IP Space – Large Cap 
o Ethicon Endo-Surgery, Inc. 
o Dusa Pharmaceuticals, Inc 
o The Boeing Company 
o Koninklijke Philips Electronics N.V. (Philips) 
o Sharp Kabushiki Kaisha (Sharp. Corp.) 
o Shimadzu Corporation 
o Nellcor Puritan Bennett, Inc. 
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 Start-Ups in IP Space – Small Cap 
o HyperMed, Inc. 
o NIR Diagnostics, Inc. 
 NIR had also licensed its infrared technology to Motorola, Ortho-
Clinical Diagnostics, and Shaklee. However, the company folded 
and went into Canadian receivership in October 2008. [12] 
o Advanced BioPhotonics, Inc. 
o Lumidigm, Inc. 
o ChemImage Corporation 
o Imalux Corporation 
o Exactus, Inc. 
o Pixartix SA 
 The Swiss National Center of Competence in Research (NCCR) on 
Interactive Multimodal Information Management 
o Plain Sight Systems, Inc. 
o The Electrode Co. Ltd 
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Chapter 4. Product Development 
4.1. Design Review 
A. Design Specification 
The following inputs have been identified by experts in wound healing as 
essential components for successful monitoring of the process. 
 Device comprises a frequency domain, single source, four detector 
instrument to irradiate and measure absorption and scattering 
coefficients at multiple wavelengths, particularly in the 685 nm to 950 
nm range to effectively perform functional near infrared (fNIR) 
spectroscopy 
 Device needs to be completely free from the risk of infection 
 Device needs to not cause an immune reaction in the host tissue 
 Device needs to last several years before being replaced 
  
B. Narrative Description 
The current paradigm for monitoring of wound healing calls for a measurement 
of wound size by tracing or by digital imaging.  This superficial evaluation 
delays proper treatment and results in continuation of potentially ineffective 
treatment methods which may ultimately lead to amputation.  Near Infrared 
(NIR) Spectroscopy is a non-invasive technique by which one can analyze 
structural and functional information of living tissues in the region of 
wavelength 685 - 950 nm.  Differences in absorption reveal changes in tissue 
oxygenation and blood flow, while differences in scattering correlate to tissue 
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structure and inflammation. Results obtained from previous studies demonstrate 
that the time course of healing can be followed using this method.  The 
proposed NIR wound monitoring system would enable non-invasive evaluation 
of the effects of wound intervention.  Faster screening of products would be 
made possible, and hence the timeline and medical costs could be drastically 
reduced. 
 
C. Physical Description 
i. Optical Methods [13] 
1. This study employs a frequency domain NIR spectroscopy (NIRS) 
instrument with one source position, four detector channels, four 
wavelength diode lasers ( = 685 nm , 785 nm, 830 nm and 950 nm), 
and a source modulation frequency of 70 MHz.  A schematic of the 
device is shown in Fig. 1. 
2. Each block of the instrument is housed in a separate nuclear 
instrumentation box (NIM BINs, Mech-Tronics Nuclear) that provides 
suitable wiring for power supply, mechanical stability and most 
importantly good shielding against radio frequency (RF) 
electromagnetic cross talk. 
3. The 70-MHz RF signal (Wilmanco Corp.) with stable phase from the 
generator [Fig. 1 (block 1)] is used to supply the IQ demodulators of 
the four detectors and for modulating the emission light of the three 
laser diodes. A LD1100 laser diode driver (Thorlabs) was utilized for 
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type A laser diode (laser anode and photodiode cathode are common), 
and we built two diode drivers using IC3C07 (Sharp Corp) chip for 
type C laser diodes (laser cathode and photodiode anode are common). 
The power stability of the lasers, measured with a standard 
powermeter (ThorLabs), is better than ±3-5*10-2 mW/h.  
4. The lasers and drivers are placed in Fig. 1 (block 2), and are coupled to 
62.5/125 multimode fibers.  The two 1 2 optical switches (Dicon 
Fiberoptics, Inc.) and their drivers [shown in Fig. 1 (block 3)] are 
controlled through a Visual Basic code. The light from the optical 
switches is fed to the 62.5- m source fiber inserted in our probe [shown 
in Fig. 1 (block 4)] and illuminates the experimental animals, one 
wavelength at a time.  
5. The output power at the end of the source fiber ranges from 5 to 7 
mW, for all three wavelengths. The scattering light is being picked up 
by four detector bundle fibers (Dolan Jeuner Corp) with diameters 0.5 
mm (first and second detectors) and 1 mm (third and fourth detectors) 
and registered by four fast avalanche photodiodes from Hamamatsu 
(C5331-03), mounted in four separate NIM boxes [Fig. 1 (blocks 6–
9)]. 
6. The electrical RF signal is amplified by a first amplifier (ZFL-500LN, 
Mini-Circuits), filtered by a band filter at 70 MHz, further amplified 
by a second amplifier (ZFL-500HLN, Mini-Circuits) and fed to the I/Q 
demodulator (MIQY-70D, Mini-Circuits). The outputs of the IQ 
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detector are the cosine (I) and sine (Q) low-frequency components of 
amplitude and phase shift relative to the reference signal from the RF 
generator. These signals are further digitized by a 16-bit data 
acquisition board (PCI-6036E, National Instruments shown as Fig. 1 
(block 10). 
 
ii. Instrument Calibrations 
1. The measured light amplitude and phase shift consist of both 
instrument and sample contributions. The amplitude obtained in each 
channel depends on the transmission of the optical fibers, the 
sensitivity of the avalanche photodiode, the gain of each detector block 
and the coupling of the fibers. The phase shift may be different in each 
channel because the optical and electrical signal delay depends on 
fiber length and coupling, length of RF coaxial cables, and delays in 
the detector circuits.  
2. Instrument calibration is designed to allow for separated variability 
due to the instrument hardware components from sample and 
measurement variability. An equidistant probe is constructed to 
conduct the first instrument calibration. The source and four detectors 
fibers are inserted in a Teflon probe with the same source-detector 
separation of 12 mm. The probe is placed inside the intralipid solution 
(infinite geometry) or on the liquid surface (semi-infinite geometry). 
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3. The detector areas are assumed to be so small that the fluence rate 
does not change essentially over the surface of the detector fibers. Fig. 
2 illustrates the calibration procedure, consisting of an intensity and a 
phase correction.  
4. On the graph, circles represent raw experimental data. The difference 
in measured amplitude Aical and phase ical  by various detectors 
reflects the different response of each channel at the same fluence of 
scattered light because source-detector separation is the same at 12 
mm.  
a. Taking the amplitude of the first detector as the standard (A1cal), 
three coefficients are calculated: Ki = A1cal / Aical , where i = 2, 3, 
and 4 and Aical represents the amplitudes of the second, third, and 
fourth detector correspondingly. The subscript cal stands for 
calibration.  
b. Using these coefficients Ki for calibration, the experimental data 
are changed to a horizontal line at the level of the amplitude of 
the first detector. This is shown on the graph by the diamond 
shape points. The calibration coefficient for the first detector is 
K1 = 1 since we used the first detector as our reference point. 
5. For phase correction the same procedure is used and the difference 
calculated from 1 =1cal  - ical  of the phase for the second, third, and 
fourth detector relative to the first detector. 
 
 
47
a. Using these differences to correct the calibration data, i the 
value of phase shift for all detectors is obtained. The difference 
in phase shift for the first detector is 1 = 0. 
6. The second calibration is conducted to define the region of saturation. 
Light from the diode laser is passed through the variable fiber 
attenuator and fed to the fiber optical splitter 1  2. 
7. One output fiber from the splitter is inserted in the probe that is placed 
in the intralipid solution, while the second fiber is connected to a 
power meter. During this calibration we attenuate the power of the 
incident light by changing the transmission of the attenuator. 
8. The logarithm of the output amplitude in mV is plotted as a function of 
the logarithm of incident light power in mW for the same source-
detector separation. Saturation occurs at an output signal of around 
100 mV.  
a. Typical magnitudes of the I and Q signals were in the range of 2–
70 mV. Offset for the instrument, defined as the signal measured 
without any light, has not exceeded 500 V, with an average 
value around 250 V. Offset shall measured before every 
experiment with a human subject. 
9. The value of the phase shift should not change for measurements 
where the source-detector separation is constant.  The experimental 
phase is plotted as a function of the power of output light.  
 
 
48
a. The linearity range for phase is defined as the area with deviation 
from the average value of phase (horizontal line of constant 
magnitude) less than 1 degree. 
b. The linearity range for the device is >50 dB.  This experiment 
allows for calculation of the noise-equivalent power for our 
device equal to 5 pW/Hz1/2.  
c. This means that the signal to noise ratio is approximately one 
when the power of the input light signal is approximately ~ 5 pW 
for a frequency of 1 Hz. 
 
4.2. Regulatory Pathway 
A. Indications for Use Statement 
i. Specific Indications [14] 
A diffuse photon density wave (DPDW) methodology of near-infrared (NIR) 
spectroscopy is indicated for the monitoring of tissue physiology from a few 
millimeters to several centimeters below the skin or tissue surface at the site of 
chronic wounds, such as diabetic foot ulcers, venous ulcers and bed sores.  
Exposure to light in the near-infrared region (wavelengths 650-850 nm) provides 
the optimal tissue transparency, thus permitting this level of depth penetration.   
The absorption coefficient, μa, of tissue is markedly lower than its value at visible 
wavelengths. Then the dominant phenomenon of light propagation in tissue is 
multiple light scattering by cells, organelles, capillaries, and other interfaces and 
tissue structures. This is indeed the case at NIR wavelengths, where absorption of 
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hemoglobin, water, and lipids is relatively very small.  Furthermore, at a selected 
range of NIR wavelengths, the spectra of oxy- and deoxyhemoglobin are 
significantly different from each other and allow calculation of absolute 
concentrations of both types of hemoglobin and, consequently, oxygen saturation, 
if their extinction coefficients are known at the particular wavelengths.  Thus, the 
DPDW method shall yield quantitative information about blood oxygenation and 
blood volume, water, and lipid content, as well as qualitative information about 
changes of tissue structure at the chronic wound site. 
 
ii. Clinical Settings 
Specialized instruments shall be built and operated at near-infrared wavelengths 
to provide a non-invasive, quantitative assessment of the wound healing process.  
The ultimate goal is provide clinicians with a tool to effectively: 
 Evaluate and compare treatment modalities used in chronic wounds 
 Predict the healing potential of a wound before it becomes clinically 
obvious 
 Mitigate the false positive indications based on the current clinical 
paradigm 
iii. Target Population 
The target population for this monitoring methodology will consist of patients 
undergoing treatment for chronic wounds.  While the prevailing category of 
chronic wounds has typically been diabetic foot ulcers, the healing process of 
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venous ulcers, bed sores, and burns may also be monitored using the proposed 
system.     
 
iv. Anatomical Sites 
The types of wounds to be monitored are usually found in the lower extremities.  
This procedure is truly non-invasive in that a region spanning from a few 
millimeters to several centimeters below the skin or tissue surface at the wound 
site may be assessed without making contact.  The chronic wound environment 
is characterized by: 
 Ischemia (impaired blood circulation and oxygen delivery). 
 Defects in collagen synthesis. 
 Peripheral neuropathy: loss of sensory sensation, minor injury of the 
foot goes unnoticed and untreated. 
 Impaired immune response (causing infection). 
        
B. 510(k) Statement 
i. Substantial Equivalent 
The following devices have been identified as applicable predicate devices, all of 
which have received a designation of substantial equivalence by the FDA, CDRH 
division.  Given the similar intended uses and applications, it is concluded that the 
present device shall be labeled as a Class II medical device, as is the case for the 
predicate devices listed below. 
 K050014: NIR Diagnostics Inc., HemoNIRLabTM 
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 K061848, K073656: HyperMed Inc. OxyVuTM-1 Hyperspectral Tissue 
Oxygenation Measurement System 
 K061919: Hutchinson Technology, Inc., InSpectra StO2 Tissue 
Oxygenation Monitor 
  
C. Sterilization and Shelf Life 
Tegaderm transparent sterile dressing (3M Health Care) shall be used to cover the 
fiber optic probe.  The probe is the only component of the device to come in 
direct contact with the patient.  To eliminate the introduction of infectious agents, 
it will be recommended that the device be stored in a sterile environment, and 
frequently be cleaned using gamma radiation or antimicrobial solvents.  The shelf 
life consideration is not applicable in this case, as the device is expected to 
perform adequately for the duration of its mechanical and optical sustainability. 
 
D. Biocompatibility 
The issue of biocompatibility shall be considered briefly since there is minimal 
administration of natural or synthetic materials in vivo.  The Tegaderm dressing 
may come into contact with the wounds to be monitored, and comprises 
Poly(dimethyl siloxane) (PDMS), which represents an FDA-approved synthetic 
elastomeric biomaterial.  With regards to fNIR radiation, the levels introduced 
during monitoring is such that is generally regarded as safe (GRAS) as evidenced 
by the numerous ongoing research projects sponsored by the NIH and granted 
approval at the institutional level in addition to prior FDA device approvals. 
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E. Software 
The current device incorporates a unique software system specifically designed 
for controlling the radiation source, manipulating the four probe fibers, displaying 
and storing the measurements, and extrapolating the data for interpretation.  It was 
developed using VisualBasic and provides the capability of reading the phase 
shift and amplitude in measuring oxy- and deoxyhemoglobin concentration base 
on this absorption and scattering data collected.  The next generation prototype is 
scheduled to incorporate the LabVIEW platform.  LabVIEW is a proprietary 
product of National Instruments.  Unlike common programming languages such 
as C or FORTRAN, LabVIEW is not managed or specified by a third party 
standards committee such as ANSI.  While this shall serve the purpose of research 
validation, this will create an impediment to commercialization.  Thus, the 
market-ready device would require a software system running an independently 
developed platform to avoid third party licensing issues.   
 
F. Risk Management 
As a critical component of the design process, a risk management plan has been 
developed to comply with the medical device international standard ISO 14971 to 
ensure that unacceptable risks are identified and managed accordingly.  This shall 
be a collaborative effort among the engineers (design, manufacturing, and 
quality), clinicians and credible risk management experts.  The quality engineers 
will oversee this process internally and determine the scope of planned activities 
and life cycle phases for which each element of the plan is applicable. 
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Compliance will be determined by subjective third party inspectors.   An internal 
compliance auditor will also be retained for the collection and review of relevant 
production and post-production information in accordance with FDA Good 
Manufacturing Practices (GMP).  In addition, this individual will be primarily 
responsible for the conduction of Medical Device Reporting (MDR), as outlined 
in 21CFR803.   
 
An initial risk analysis was performed using both a Failure Modes and Effects 
Analysis (FMEA) (Table 20) and a Preliminary Hazard Analysis (PHA) (Table 
21), which also provides a means for risk evaluation and control. 
 
 
Table 20: Failure Modes and Effects Analysis Chart 
Failure Mode Effect Likelihood Detection Severity 
Risk 
Priority 
Number 
Improper source 
calibration 
Inaccurate 
data 
collection 
1 1 10 10 
Laser 
malfunction  
Improper 
scattering and 
absorption 
coefficients  
1 2 10 20 
Cable pin 
detachment 
Connection 
between 
monitor and 
CPU 
compromised 
4 1 10 40 
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Table 20 (continued) 
 
Laser burnout 
Zero 
scattering and 
absorption 
measured 
3 2 10 60 
Difficulty in 
controlling 
starting and 
stopping (since 
no button 
directly on laser 
probe) 
Not all five 
probe fibers in 
constant 
contact with 
tissue surface, 
jeopardizing 
measurement 
accuracy 
5 3 7 105 
 
 (Scale: 1-10, Likelihood/Severity: 1=least, Detection: 1=easiest)   
 
 
 
Table 21: Hazard Analysis Chart 
 
 
 
 
Hazard Causes Initial Risk
Risk control 
measures 
Tests 
performed 
Residual 
Risk 
Accept-
able? 
1.0  Energy Hazards 
1.1  Radiation Exposure 
1.1.1 
Exposure to 
NIR 
electromagnetic 
radiation during 
device usage 
IV-E
Maintain 
exposure level 
within proper 
safety range 
Routinely 
check 
radiation 
exposure level 
IV-E Y 
2.0  Biological Hazards – Not Applicable 
3.0 Environmental Hazards 
3.1 Non-sterile environment 
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 Table 21 (continued) 
 
 
 
 
Hazard Causes Initial Risk
Risk control 
measures 
Tests 
performed 
Residual 
Risk 
Accept-
able? 
3.1.1 
Contaminated 
probe cover 
dressing 
II-D 
Use unopened 
disposable 
sterile 
Tegaderm for 
each use 
N/A II-E Y 
3.1.2 
Contaminated 
probe fibers II-C 
Use unopened 
disposable 
sterile probes 
for each use 
N/A II-E Y 
3.1.3 
Contaminated 
clinical sites 
II-C 
Ensure clean 
room 
environment 
with sterile 
gloves and 
proper attire 
Perform 
routine 
environmental 
monitoring 
II-D Y 
4.0 Hazards related to device usage 
4.1 Injury to patient 
4.1.1 User error II-E 
Extensive 
training 
Performance 
evaluation 
II-E Y 
4.1.2 
Faulty 
equipment 
II-E 
Establish 
equipment 
usage limit 
Maintain 
equipment 
usage log 
II-E Y 
4.1.3 
Wound 
aggravation 
III-D
Application of 
light pressure 
while wearing 
sterile gloves 
during data 
collection 
Absorption 
data and 
wound photos 
taken will 
clearly 
indicate 
III-E Y 
4.2  Injury to operator 
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Table 21 (continued) 
 
 
(Risk Index: I=Catastrophic, II=Significant, III=Marginal, IV=Negligible; 
A=Frequent, B=Probable, C=Occasional, D=Remote, E=Improbable) 
 
 
Hazard Causes Initial Risk
Risk control 
measures 
Tests 
performed 
Residual 
Risk 
Accept-
able? 
4.2.1 
Struck by 
system 
components  
II-D 
Development of 
miniaturized 
version of 
system to 
consolidate 
components into 
single portable 
unit 
N/A III-E Y 
4.2.2 
Wound 
exposure 
III-D
Sterile gloves 
worn during 
data collection
Periodic blood 
testing 
III-E Y 
5.0 Inappropriate, inadequate or overcomplicated user interface 
5.1 Complications 
5.1.1 
User error 
associated with 
manipulating 
laser probes 
IV-D
Modification of 
probe design to 
include control 
switch at probe 
fiber location 
Clinical 
testing IV-E Y 
5.1.2 
User error 
associated with 
data collection 
and 
interpretation  
IV-D
Development of 
simplified visual 
display to show 
current readings 
with ability to 
compare to 
measurement 
history and 
expected range 
Clinical 
testing IV-E Y 
6.0 Hazards arising from functional failure, maintenance, aging, and contributory 
factors – Not Applicable 
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G. Verification  
i. Viability Test [15] 
How do the measurements compare to optical imaging? 
A pilot human study was conducted to evaluate the potential of using Diffuse 
Photon Density Wave (DPDW) methodology at near infrared (NIR) 
wavelengths (685-830nm) to monitor changes in tissue hemoglobin 
concentration in diabetic foot ulcers. Hemoglobin concentration was measured 
by DPDW in 12 human wounds for a period ranging from 10 to 61 weeks. In all 
wounds that healed completely, gradual decreases in optical absorption 
coefficient, oxygenated hemoglobin concentration, and total hemoglobin 
concentration were observed between the first and last measurements. In non-
healing wounds, the rates of change of the above properties were nearly zero or 
slightly positive, and a statistically significant difference (p<0.05) was observed 
in the rates of change between healing and non-healing wounds. Differences in 
the variability of DPDW measurements over time were observed between 
healing and non-healing wounds and this variance may also be a useful 
indicator of non-healing wounds. 
 
ii. Functional Test [15] 
Are the measured coefficients of absorption and scattering within the 
normally expected range? 
In both healing and non-healing wounds, values of the NIR absorption 
coefficient μa at the wound center and wound edges have consistently measured 
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greater than values of μa at the control (non-wound) sites. In all measurements 
of healing wounds, the values of μa at the wound center and edge sites 
decreased and converged to the values measured at the control sites.  In contrast, 
values of μa in all non-healing wounds remained greater than the control sites 
and did not converge over the course of the study. 
 
iii. Probe Depth Capability Test 
For calculated values of total hemoglobin concentration, trends are similar to 
those observed for optical absorption. 
 
iv. Stability Test (calibration via control sample) [15] 
Were control measurements accurate? 
An optical phantom made of silicone (XP565 – Silicones, Inc.) with dispersed 
particles of TiO2 (diameter 0.9 to 1.6 μm - Alfa Aesar) to act as scatterers and 
carbon black acetylene (50% compressed, diameter 0.042 μm – Alfa Aesar) to 
absorb light [17] was measured before each patient measurement session.  The 
measured absorption coefficients from the silicone phantom Standard error 
remained at less than 3% throughout the period of the study. 
 
v. Testing the Effects of Location [15] 
Was NIR absorption greater in center of wound than edges? 
All diffuse NIR measurements were conducted prior to wound debridement on a 
weekly or biweekly basis. During each measurement session, the wounds of 
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each patient were interrogated using the NIR instrument in up to ten different 
locations. Measurement locations were chosen based on the geometry and size 
of each wound, and can be classified into four general locations: (1) directly on 
the wound, (2) on intact skin at the edge of the wound, (3) on non-wound tissue 
of the contralateral limb symmetric to the wound location if available, (4) on 
non-wound tissue on the ipsilateral limb at a distance of at least 2 cm from the 
wound.   
   
vi. Reproducibility [15] 
Previous research on the application of diffuse near infrared methodology to 
assess wound healing in animal models has led to the development of a 
hypothesis on the expected behavior of near infrared (NIR) absorption 
coefficients during the course of healing [16, 17]. A study of acute wound 
healing in hairless rats demonstrated that optical absorption coefficients 
increased gradually from the time a wound was inflicted until the time it closed, 
and histopathological and immunohistochemical analysis verified that these 
optical increases were related to increases in blood vessel density [17]. 
Following this study, it was hypothesized that if DPDW measurements were 
continued after closure of the wound, a decrease in optical absorption would be 
expected during the late proliferative phase of wound healing as vessel 
density/blood volume decreased to normal levels. This decrease in absorption 
was recently confirmed through a pilot study of wound healing in seven obese 
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Zucker Diabetic Fatty (ZDF) rats in which full-thickness wounds were 
monitored using DPDW methodology.  
The time dependence of NIR optical absorption for human patients is expected 
to be different from that observed during the animal studies. Human patients are 
first seen when they have already developed chronic wounds, corresponding to 
an elevated yet constant absorption level (indicative of non-healing) in this 
healing model. Any progress in healing manifests itself by a decrease in the NIR 
absorption coefficient, and a convergence to the value of non-wound tissue. In 
wounds that do not heal, the level is not expected to converge with non-wound 
tissue.  The rates of change in healing and non-healing wounds are in agreement 
with the hypothesized healing model and may provide the basis for a 
quantitative “healing index” that helps clinicians to distinguish healing from 
non-healing wounds. The predictive capability of the rates of change in DPDW 
data would need to be determined through a study of more patients with 
measurements taken at more time points. 
 
vii. Packaging 
The device would likely come in a shrink-wrapped cardboard box, stabilized by 
cardboard inserts with the components cunshioned by a foam padding.  The 
probe should be bubble-wrapped for added protection.  The device will be 
assessed for damage (cracks, warps, etc.) due to shipping and handling.  
Packaging would be tested for strength to determine probability to future loss of 
integrity or function. 
 
 
61
 
H. Validation 
i. Performance Test [15] 
Did trends change with different wound locations?   
In order to analyze the clinical data the investigators have identified common 
parameters that describe the trends observed and are representative of the 
clinical outcomes. In this analysis, the rate of temporal change of the absorption 
coefficient at each wavelength as well as the rate of temporal change in 
hemoglobin concentration can be estimated by fitting the data from each wound 
to a linear trend line. The limited amount of experimental data collected during 
this study combined with the data accuracy do not allow the use of a more 
complicated fitting model at this time. The slopes of these trend lines 
correspond to the rates of change in optical properties with time, and have 
proven useful in quantifying the progress of a healing wound in the study.  In all 
healing wounds negative rates of change were observed for the optical 
absorption coefficient at each wavelength, the total hemoglobin concentration, 
and the oxy-hemoglobin concentration. In all non-healing wounds the rates of 
change for the above properties were close to zero or slightly positive. The rate 
of change for deoxy-hemoglobin concentration was close to zero in both healing 
and non-healing wounds. 
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ii. Use of Device [15] 
Temporal changes in the concentration of hemoglobin derived from DPDW 
measurements of the optical absorption coefficient in diabetic foot ulcers can be 
used to monitor healing progress. These changes can be quantified by 
calculating the linear rate of change and the week to week variability in optical 
absorption coefficient and hemoglobin concentration over time. These metrics 
were used to distinguish healing from non-healing wounds in a study of human 
diabetic foot ulcers, indicating that DPDW methodology at near infrared 
wavelengths may be able to provide wound care clinicians with objective and 
quantitative data to help in the assessment of overall wound health when 
deciding on treatment options. 
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Chapter 5. Commercialization Strategy 
5.1. Reimbursement Consideration 
The following is excerpted from the market research report by Kalorama: Wound 
Care Skin Ulcers, February 2009 [11] 
Third-party payers require information to justify medical necessity for wound 
care.  Without such documentation, payment for services and products will be denied. 
Some of the requirements for wound documentation are: 
• Location and measurement of the wound (including width, length, and depth) 
• Assessment of wound healing progress 
• Turning and positioning schedules, if indicated 
• Assessment and documentation of general skin condition 
• Evaluation and documentation of nutritional status 
• Use of protective or pressure reducing devices, if indicated 
• Topical treatments used and the outcomes of care  
Every claim submitted for reimbursement is based on the premise that the care 
rendered or the supplies provided were medically necessary and appropriate to treat the 
wound.  Generally, the first question a clinician asks after learning about a new wound 
treatment modality and deciding it has clinical merit is "How is it reimbursed?" This 
question is so vague that it is often impossible to give a simple answer. For example, to 
answer this appropriately, the following information is necessary: 
1. The clinical setting (acute care, rehabilitation hospital, skilled nursing facility, 
home health agency, physician office, outpatient clinic, patient at home without services; 
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2. The payer type (Medicare, Medicaid, managed care organization, HMO, 
supplemental insurer, private insurer, veterans administration, workman's compensation, 
other); 
3. The coverage policy for the payer; 
4. The medical necessity requirements for coverage; 
5. The patient's diagnosis; 
6. The coding assigned for billing; 
7. The fee schedule, assigned payment amount, or procedure for establishing 
payment. 
Another commonly asked question is "What is the code?" Again, this may not be 
easy to answer. For example, a company may be awaiting a coding verification from the 
SADMERC or a decision from either the HCPCS Coding Panel or the American Medical 
Association.  
 
CMS codes 
Diagnostic Technology: - Dopplers: CPT: 93922, 93923, 93924, 93965, 
93970, 93971  
Nutritional Management: - B4150, B4151, B4152, B4153, B4154, B4155, 
B4156  
 
Before the product can even be considered for reimbursement, it has to be on the 
market for six months.  The key factors are whether or not the product or service is a 
covered benefit in the particular clinical setting where provided and whether the amount 
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paid is appropriate.  Clinicians must learn how to document assessments, interventions, 
patient compliance to treatment plan, and outcomes of wound care in a way that supports 
coverage and payment for both products and their services.  
The Centers for Medicare and Medicaid Services (CMS) in connection with the 
Deficit Reduction Act of 2005, has identified eight preventable events that will no longer 
be reimbursed. This was done to contain costs by rejecting payment of the higher 
diagnostic category when these events occur as a secondary diagnosis in acute care 
settings. Pressure ulcers have been identified as one of the conditions that will no longer 
be reimbursed by CMS.  In 2007, CMS reported 257,412 cases of preventable pressure 
ulcers as secondary diagnoses. The average cost per case in which pressure ulcers were 
listed as a secondary diagnosis is estimated to be $43,180 per hospital stay. The incidence 
of new pressure ulcers in acute care patients is around 7 percent, with wide variability 
among institutions.  As of October 2008, the CMS will no longer reimburse hospitals for 
the treatment of eight hospital-acquired conditions, including pressure ulcers and various 
types of infections. This action makes implementing a pressure ulcer prevention program 
a priority.  
 
5.2. S.W.O.T Analysis 
[S.W.O.T. stands for Strengths, Weaknesses, Opportunities and Threats; definitions of 
each are below.] 
Strengths 
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Strengths describe the positive attributes, tangible and intangible attributes, internal 
to the product/service/technology. They are within control. Strengths capture the positive 
aspects internal to your product that adds value or offer a competitive advantage. 
 The present Diffuse Photon Density Wave (DPDW) near infrared (NIR) methodology 
enables an accurate and objective assessment of wound healing. 
 This technique is purely non-invasive, presenting a minimal discomfort and risk to 
the patient. 
 The technique is relatively simple to perform, providing for a significant amount of 
data to be captured in a relatively small time period. 
 Multiple embodiments of the device and method are the subject of pending U.S. and 
international patents. 
 Preliminary studies have been published in peer-reviewed journals, which indicates 
the technical viability of this concept. 
 This research project has received multiple rounds of funding, including awards 
specifically designated for translational medical applications. 
 The lead investigator has been interviewed for a recent Frost & Sullivan market 
research report identifying this project as an emerging technology in the field of NIR.   
 The general design of the device shall lend itself to a flexible cost and pricing 
structure. 
 
Weaknesses 
Weaknesses are internal factors that are within your control that detract from the 
ability to obtain or maintain a competitive edge.   Weaknesses capture the negative 
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aspects internal to the product/service/technology that detract s from the value or 
constitutes a competitive disadvantage.  
 While patents have been filed, currently none have issued.  It will be several years 
before any pass toward issuance as the first PCT application was filed in April 2009 
 The current prototype is not sufficiently small to make it easily portable.  This 
constitutes a future aim of the development process. 
 The uncertainty surrounding the final prototype design makes it difficult to anticipate 
a representative financial model.  
 There is an element of difficulty in controlling the starting and stopping operations of 
the device as the control buttons are located on the central unit.  This has the potential 
effect of having not all 5 probe fibers in constant contact with the tissue surface, 
which may compromise measurement accuracy.  Placing a control button directly on 
the laser probe would alleviate this problem.      
 
Opportunities 
Opportunities assess the external attractive factors that represent the reason for the 
product/service/technology to exist and prosper. Opportunities may be the result of 
market growth, lifestyle changes, resolution of problems associated with current 
situations, positive market perceptions or the ability to offer greater value that will create 
a demand for the product/service/technology.  
 The device and monitoring activity shows great promise for serious medical 
reimbursement consideration due to the tremendous cost savings potential. 
 
 
68
 Such a monitoring device would also present value to the research community as a 
product validation tool applicable to the following emerging technology segments of 
the wound care market: 
o Electrical Stimulation Therapy 
o Electromagnetic Therapy 
o Growth Factors 
o Honey-based Dressings 
o Low-level Laser Therapy 
o Maggot Therapy 
o Nanotechnology 
o Negative Pressure Wound Therapy (NPWT) 
o Oxygen Therapy 
o Therapeutic Ultrasound 
 Pressure ulcers have been identified as one of the conditions that will no longer be 
reimbursed by the Centers for Medicare and Medicaid Services (CMS) in connection 
with the Deficit Reduction Act of 2005.  This action makes implementing a pressure 
ulcer prevention program a priority. Smith & Nephew developed a program called 
BRIDGES.  The program is designed to improve assessment of high-risk patients, 
standardize practice protocols, develop customized core formularies, drive proper 
product selection and utilization, improve protocol compliance, and track sustainable 
repeatable results.  The present technology may be of particular interest in 
conjunction with this initiative.  [11] 
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 Third-party payers require information to justify medical necessity for wound care.  
Without such documentation, payment for services and products will be denied. 
Among the requirements for wound documentation is the assessment of wound 
healing progress.  [11] 
 
Threats 
Threats include external factors beyond control that could place the marketing 
strategy at risk.  A threat is a challenge created by an unfavorable trend or development 
that may negatively impact the prospective opportunity.  
 An inability to secure a 510(k) FDA device approval could potentially damage the 
marketability of this technology.  This is considered a low probability event based on 
the predicate devices previously approved under the 510(k) paradigm.   
 There is a threat of competing technology, such as the product line offered by 
HyperMed, Inc. 
 An element of uncertainty exists regarding the reimbursement paradigm of the 
clinical application of this technology.  There is currently no CMS code designated 
specifically for wound monitoring, so it is likely a new code would be sought.  This 
can be an arduous process.   
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5.3. Potential Licensees 
 
 
 
Table 22: Listing of Prospective Licensees 
 
Company Field(s) of 
Use 
Comments Primary Point-of-Contact 
Lumina 
Diagnostics  All 
Wharton student 
NewCo, took 
option but no 
longer appear 
interested 
Pitamber Devgon, 
devgon@wharton.upenn.edu 
The 
Incubation 
Factory 
All 
Virtual 
technology 
incubator, 
privately funded  
Bill Rowe, 
browe@theincubationfactory.com
Smith and 
Nephew 
All, Wound 
Healing 
Big player in 
wound healing 
market 
James Lavan 
Emerging Business Specialist & 
New Technology Manager 
Wound Management 
james.lavan@smith-nephew.com 
NIRx 
Medical 
Technologies 
All, Wound 
Healing 
Measurement
SUNY spinout 
founded in 1993 
Randall Barbour, CEO, 
Randall.Barbour@downstate.edu 
Med-
Surgical 
Instruments, 
Inc. 
All, Wound 
Healing 
Measurement
Local OEM who 
could either 
distribute or 
submlicense 
Dr. Atiqueh Khan, CEO, 
atiquehkhan@yahoo.com 
 
 
 
5.4. Conclusions and Recommendations 
 
Overall this project holds great promise for the future of wound care.  The ability to 
quantitatively measure wound healing shall enable clinicians to assess the progress 
attributable to a given treatment.  This information can be used to prescribe further 
treatment protocols in a wound care facility or determine the viability of therapies in 
development.  This represents a substantial market opportunity as it addresses a currently 
unmet clinical need.  If previous data trends continue in the ongoing investigations, and 
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the device is shown to be safe and effective for human wound monitoring, this 
technology shall draw considerable commercial interest.  While the path to market is not 
completely clear, 510(k) approval and reimbursement remain within the realm of 
possibilities.  These will have an impact on the distribution model ultimately adopted, 
and shall require domain expertise to navigate the process of each.  These activities may 
be incorporated into the development timeline, as the technology has advanced well 
beyond the proof-of-concept stage and approaches market readiness.   
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